Tag Archives: Xalkori

Takeda eyes Alunbrig earlier lung cancer use as 2-year data trounce Pfizer’s Xalkori

Pfizer’s aging Xalkori is the drug to beat in ALK-positive non-small cell lung cancer arena. And that’s just the arena Takeda is aiming for with earlier use of its own treatment Alunbrig. After 25 months of treatment, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC, as assessed by… Read More »